British Menopause Society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer

Marsden, Jo; Marsh, Mike; Rigg, Anne

doi:10.1177/2053369118824920

Cited by 17 publications

(5 citation statements)

References 83 publications

(166 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В качестве 1-й линии терапии менопаузальных расстройств у женщин с эстрогензависимыми онкологическими заболеваниями органов репродуктивной системы используются негормональные фармакологические и нефармакологические методы коррекции [43].…”

Section: лечение менопаузальных симптомовunclassified

Managing menopausal symptoms in patients with hormone receptor-positive gynecologic cancers

et al. 2020

View full text Add to dashboard Cite

Young women with reproductive tract neoplasms who receive treatment leading to termination of ovarian function often suffer from menopause symptoms that contribute to dramatic drop in quality of life. Climacteric symptoms in women with iatrogenic menopause are more severe than in case of natural menopause, especially in women with reproductive tract neoplasms. They lead to dramatic drop in quality of life and are one of the main reasons to stop applying endocrine therapy in women with hormone-positive tumors, which leads to decrease in disease free survival and to decline the prognosis. The most effective treatment option for climacteric symptoms of moderate to severe degrees is menopause hormone therapy; however, such therapy is not suitable for patients with estrogen-dependent tumors in past medical history due to the likelihood risk of progression of cancer, as well as the risk of venous thrombosis, the frequency of which in cancer patients increases. Non-hormonal pharmacological and non-pharmacological correction methods are used as first-line therapy for menopause disorders in women with estrogen-dependent tumors of the reproductive system. Among non-hormonal non-pharmacological correction methods actively study such methods as acupuncture, yoga, exercise to control weight, and a diet rich in phytoestrogens. The most effective non-hormonal methods of correcting vasomotor symptoms are serotonin and norepinephrine reuptake inhibitors. However, currently in Russia these drugs can be prescribed only by a psychiatrist. The finding of effective and safe non-hormonal methods to correct menopause symptoms in women with hormone-positive reproductive tract tumors is the important task in practice among doctors in different specialties.

show abstract

Section: лечение менопаузальных симптомовunclassified

Managing menopausal symptoms in patients with hormone receptor-positive gynecologic cancers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…10,11 Vaginal hormonal estrogen remains the first-line hormonal therapy in the United Kingdom for breast cancer survivors experiencing genitourinary symptoms of menopause. 12, 13 Studies have shown that vaginal estrogen effectively relieves the GSM and significantly improves vaginal mucosal health and vaginal pH in postmenopausal women. 5 Furthermore in healthy postmenopausal women, the Women's Health Initiative observational study determined that the risk of breast cancer was not increased following the use of vaginal estrogens.…”

Section: Introductionmentioning

confidence: 99%

A systematic review of randomised clinical trials – The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors

Hussain,

Talaulikar

2023

Post Reprod Health

View full text Add to dashboard Cite

Therapies utilised in breast cancer management have been found to induce or worsen the genitourinary symptoms of menopause (GSM), a group of physical symptoms associated with the systemic loss of estrogen. These symptoms are often undertreated due to concerns surrounding cancer recurrence, especially when considering treatments with possible pro-estrogenic effects. As breast cancer prognosis continues to improve, clinicians are increasingly focussing on managing these symptoms amongst survivors. This systematic review primarily aimed to determine the risk of breast cancer recurrence amongst survivors using vaginal hormones and selective estrogen receptor modulator therapies recommended for use in GSM in the United Kingdom amongst currently published randomised clinical trials (RCTs). The secondary aim was to determine whether these RCTs demonstrated a significant rise in serum estrogen levels following the use of these therapies. A literature search revealed three RCTs suitable for assessment, two evaluating vaginal estrogen and one evaluating vaginal DHEA treatment. Our review determined that amongst published RCTs, no studies have aimed to assess for breast cancer recurrence; however among the studies observing for serious adverse effects of vaginal estrogen preparations, none have reported an increased incidence. Furthermore, these studies did not report a persistent or significant increase in serum estrogen levels following the use of vaginal estrogen products and low concentration (3.25 mg/day) DHEA gel. Larger RCTs studying commonly used vaginal preparations and selective estrogen receptor modulator treatments for GSM over longer follow-up periods will be vital to better assess the risk of breast cancer recurrence in survivors receiving these treatments.

show abstract

“…The broad literature on menopause (outside of MOS) mostly adopts a biomedical lens where menopause (and by extension menopausal women) is akin to disease and deficiency (Atkinson, Beck et al., 2021). For example, menopause is defined as ovarian dysfunction (Perlman et al., 2018) or estrogenic deficiency (Marsden et al., 2019). It is almost always framed as something that needs to be managed, cured, and relieved (Krajewski, 2019).…”

Section: Introductionmentioning

confidence: 99%

“A part of being a woman, really”: Menopause at work as “dirty” femininity

Whiley

Wright

Stutterheim³

et al. 2022

Gender Work & Organization

View full text Add to dashboard Cite

show abstract

British Menopause Society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women treated for early breast cancer

Cited by 17 publications

References 83 publications

Managing menopausal symptoms in patients with hormone receptor-positive gynecologic cancers

Managing menopausal symptoms in patients with hormone receptor-positive gynecologic cancers

A systematic review of randomised clinical trials – The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors

“A part of being a woman, really”: Menopause at work as “dirty” femininity

Contact Info

Product

Resources

About